{"prompt": "['Trial ID: LP0162-1325', 'Date: 14-Aug-2018', 'Version: 4.0', 'Page 93 of 169', '12.3 Statistical analysis', '12.3.1 Disposition of subjects', 'Subject disposition will be presented separately for subjects in initial treatment, in', 'maintenance treatment, and in open-label treatment. For all randomised subjects the reasons', 'for permanent discontinuation of IMP and for leaving the trial in the initial treatment period', 'will be presented by last visit attended and by treatment group. For the subjects in the', 'maintenance safety analysis set, the reasons for permanent discontinuation of IMP and for', 'leaving the trial or treatment arm will be presented by last visit attended and by the assigned', 'treatment group at Week 16. For the subjects in the open-label safety analysis set, the reasons', 'for permanent discontinuation of IMP and for leaving the trial will be presented by last visit', 'attended.', '12.3.2 Demographics and other baseline characteristics', 'Descriptive statistics of demographics and other baseline characteristics will be presented', 'separately for all randomised subjects and for the maintenance analysis set. The presentations', 'will be overall and by treatment group. Presentations of age, sex, ethnicity, race, baseline', 'disease severity, and Worst Daily Pruritus NRS weekly average at baseline will also be given', 'by region and by baseline disease severity (IGA 3 or 4).', 'Demographics include age, sex, race, and ethnicity. Other baseline characteristics include vital', 'signs (including height, weight, body mass index), duration of AD, concurrent diagnoses', '(from medical history and indications for concomitant medication), concomitant medication,', 'and previous AD treatments.', '12.3.3 Exposure and treatment compliance', '12.3.3.1 Exposure', 'Exposure to treatment will be presented for the safety analysis set (initial treatment), the', 'maintenance safety analysis set (maintenance treatment), and open-label safety analysis set', '(open-label treatment) as days of exposure per treatment group.', 'For the full trial period, the days of exposure on tralokinumab irrespective of treatment group', 'will be summarised - subtracting potential periods on placebo - for the safety analysis set.', 'eDoc-00631888 - Version 4.0']['Trial ID: LP0162-1325', 'Date: 14-Aug-2018', 'Version: 4.0', 'Page 94 of 169', '12.3.3.2 Treatment compliance', 'Adherence to treatment regimen will be recorded in the eCRF. Where home-use is', 'appropriate, the subject will be asked at each trial visit if IMP was administered as instructed.', 'The log of drug administration may be used as source. If any complications or deviations in', 'administration are observed, these will be described as protocol deviations.', 'Adherence will be presented for the safety analysis set (initial treatment) and for the', 'maintenance safety analysis set (maintenance treatment) for each treatment group. Adherence', 'will also be presented for the open-label safety analysis set (open-label treatment).', '12.3.4 Multiple testing procedure', 'To control the overall type 1 error rate, the primary analyses of the primary estimands for the', 'primary and secondary endpoints for the initial and maintenance treatment will follow the', 'testing procedure outlined in Panel 15. The hypothesis relating to a specific endpoint cannot', 'be rejected unless all hypotheses relating to endpoints earlier in the hierarchy are also', 'rejected.', 'Panel 15 Testing procedure for primary, secondary, and maintenance endpoints', 'IGA 0/1 at Week 16', 'Primary endpoint', 'EASI75 at Week 16', 'Primary endpoint', 'Secondary endpoints', '1%', '4%', 'Maintenance endpoints', 'SCORAD at Week 16', '1. IGA 0/1 at Week 52 between Q2W and Placebo', 'Pruritus at Week 16', '1%', '2. EASI75 at Week 52 between Q2W and Placebo', 'DLQI at Week 16', '3. IGA 0/1 at Week 52 between Q4W and Placebo', '4%', '4. EASI75 at Week 52 between Q4W and Placebo', 'Multiplicity adjustment', 'Multiplicity adjustment', 'using the Holm method', 'using sequential testing', 'Arrows indicate order of testing when superiority is shown for all endpoints within a box.', 'DLQI, Dermatology Life Quality Index; EASI75, at least 75% reduction in Eczema Area and Severity Index', \"score; IGA, Investigator's Global Assessment; Q2W, every 2 weeks; Q4W, every 4 weeks.\", 'eDoc-00631888 - Version 4.0']\n\n###\n\n", "completion": "END"}